Pricing Log in Create free account
Friday 6 November 2026 Export ONC’s income statement to Excel — free account

BeOne Medicines Ltd. - Sponsored ADR

ONC Healthcare Biotechnology

BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.

Revenue
+33.8%
EPS
+143.7%
Free cash flow
+33.6%
Total debt
+491.3%

Quarter to September 2026, against a year earlier

407.66 20.41 +5.27%
Market cap
$40.4B
P/E
65.9×
Fwd P/E
48.8×
Dividend yield
—
F-score
7/9
Altman Z
5.25
Beneish M
−2.73
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

BeOne Medicines Ltd. - Sponsored ADR (ONC) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, BeOne Medicines Ltd. - Sponsored ADR (ONC) trades at a EV/Sales of 5.9×. Over the past ten years it has ranged from 4.1× (April 2024) to 673× (September 2017); the current reading is higher than 15% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 5.6× 23.05%
FY2024 4.5× (29.42%)
FY2023 6.4× (52.95%)
FY2022 13.7× (16.04%)
FY2021 16.3× (71.15%)
FY2020 56.5× 162.30%
FY2019 21.5× (30.90%)
FY2018 31.2× 110.30%
FY2017 14.8× (86.11%)
FY2016 107× 492.30%

Quarterly newest first

Period EV/Sales Change
Sep 2026 5.5× 20.34%
Jun 2026 4.6× (11.26%)
Mar 2026 5.1× (8.23%)
Dec 2025 5.6× (18.17%)
40 more quarters

Against its own ten years

Low 4.1× High 673×
Ten-year median 16.4×
Current reading's percentile 15

EV/Sales against peers

Company EV/Sales
BNTX BioNTech SE Sponsored ADR compare 1.8×
INCY Incyte Corporation compare 3.4×
ONC BeOne Medicines Ltd. - Sponsored ADR 5.9×
GMAB Genmab A/S Sponsored ADR compare 8.7×
ARGX argenex SE compare 8.9×
RPRX Royalty Pharma PLC compare 14.6×
INSM Insmed, Inc. compare 15.4×
RVMD Revolution Medicines, Inc. compare 172×
ROIV Roivant Sciences Ltd. compare 3,061×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on ONC